Public procurement notice: Contract Notice
Published: 2019-11-28
Buyer: The Common Services Agency (more commonly known as NHS National Services Scotland) (‘the Authority’)
Country: UK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products | 33660000
Estimated value: 52425627 GBP
Submission deadline: 2020-01-10
Award criteria: The most economic tender

Technical requirements: This framework agreement is for the supply of Antibiotic and Genito Urinary Branded and Generic Medicines to health boards across NHS Scotland.
The Goods have been split into three (3) categories, each of which is identified as a ‘Lot’. Full details of each Lot is contained in Section II.2) of this notice.
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
Supply of all antibiotic and genito urinary branded and generic medicines to NHS Scotland in a range of presentations. The Authority intends awarding a single supplier framework agreement on a line by line basis. Full details can be found within the ITT.
This framework includes the option(s) to extend for up to a total period of twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
The supply of antibiotic and genito urinary medicines for use in the provision of Central Intravenous Additives Service (CIVAS) within health boards. The Authority intends awarding a single supplier framework agreement on a line by line basis. Full details can be found within the ITT.
This framework includes the option(s) to extend for up to a total period of twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
Supply of Tobramycin, Colistemethate and Dornase Alfa in a range of presentations to NHS Scotland. The Authority intends awarding each product line as a multi supplier unranked framework agreement on a line by line basis to an envisaged maximum of six (6) Framework Participants. Full details can be found within the ITT.
This framework includes the option(s) to extend for up to a total period of twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in Regulation 58 of the Public Contracts (Scotland) Regulations 2015.
(a) potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by approved by the MHRA for all tendered Medicines at the date of framework start date;
(b) potential framework participants and any subcontractor(s) must possess valid certification of BS EN ISO 9001 or equivalent;
(c) all tendered Goods must comply with the MHRA best practice guidance on labelling and Packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design;

Eligibility requirements: Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in Regulation 58 of the Public Contracts (Scotland) Regulations 2015.

Award value: 52425627